募集资金年度存放和使用情况专项核查报告 华泰联合证券有限责任公司 关于荣昌生物制药（烟台）股份有限公司 2024 年度募集资 金存放和使用情况专项核查报告 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"） 作为荣昌生物制药（烟台）股份有限公司（以下简称"荣昌生物"、"公司"或 "发行人"）首次公开发行股票并在科创板上市的保荐机构，根据《证券发行上 市保荐业务管理办法》《上市公司监管指引第 2 号——上市公司募集资金管理和 使用的监管要求（2022 年修订）》《上海证券交易所科创板股票上市规则》《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等法律法规的 规定，对荣昌生物在 2024 年度募集资金存放与使用情况进行了核查，核查情况 如下： 一、募集资金的基本情况 （一）实际募集资金金额及资金到账情况 经中国证券监督管理委员会《关于同意荣昌生物制药（烟台）股份有限公司 首次公开发行股票注册的批复》（证监许可[2022]62 号）核准，公司于 2022 年 3 月 31 日首次公开发行普通股（A 股）5,442.6301 万股，每股面值 1 元，每股发 行价格人民币 48.00 ...

Financial Performance - RemeGen reported a significant increase in revenue, reaching approximately $150 million, representing a year-over-year growth of 25%[14]. - The company’s operating revenue for 2024 reached ¥1,716,861,688.03, a year-on-year increase of 58.54% compared to ¥1,082,953,432.23 in 2023[21]. - The net profit attributable to shareholders of the listed company for 2024 was -¥1,468,360,802.55, showing a reduction in losses compared to -¥1,511,229,176.70 in 2023[21]. - The company reported a net profit margin of 20%, reflecting strong operational efficiency and cost management strategies[14]. - The company achieved a revenue of 1.717 billion RMB in 2024, a 58.54% increase from 1.083 billion RMB in the same period last year, driven by strong sales of core products Tai'ai® and Aidiqi®[32]. - The company reported a quarterly operating revenue of ¥507,987,407.80 in Q4 2024, with a net profit attributable to shareholders of -¥396,934,163.65[25]. - The company reported a significant increase in long-term borrowings by 42.27% to RMB 1,195,878,046.86, reflecting a strategy to leverage financing for growth[149]. - The company reported a gross margin of 60%, up from 55% in the previous quarter[198]. Research and Development - The company is committed to maintaining a significant scale of R&D investment for ongoing clinical research and global clinical trials[3]. - RemeGen's total R&D investment for the year reached ¥1,539,777,961.92, an increase of 17.87% compared to ¥1,306,306,793.92 in the previous year[105]. - Research and development expenses accounted for 89.69% of operating revenue in 2024, a decrease of 30.93 percentage points from 120.62% in 2023[22]. - The company has a pipeline of products covering multiple disease treatment areas under development[3]. - The company is actively developing new products, with three new drug candidates expected to enter clinical trials by the end of the year[14]. - The company has established three R&D centers in Yantai, Shanghai, and California, focusing on preclinical development and clinical trials of innovative biopharmaceutical products[74]. - The company has a comprehensive, end-to-end R&D and industrialization system for innovative biopharmaceuticals, covering all key stages from drug discovery to large-scale production[115]. - The company has implemented a comprehensive procurement management system to ensure the quality of materials and services required for R&D and production[77]. Market Expansion and Strategy - The company is focusing on expanding its market presence in Europe and North America, targeting a 15% market share in these regions within the next three years[14]. - RemeGen anticipates continued growth, projecting revenue to exceed $200 million in the next fiscal year, indicating a growth rate of 33%[14]. - The company is actively pursuing international clinical trials for its products, including Tai'asi'pu for SLE, indicating a strategy for global market expansion[47]. - The company aims to become a leading biopharmaceutical company in China and a world-class player by focusing on the discovery, development, and commercialization of innovative biopharmaceuticals for major diseases[178]. - The company plans to commercialize and clinically develop its product RC18 (Taitasip) for various indications, having completed a Phase III trial for systemic lupus erythematosus in 2022[180]. - The company is advancing the clinical development of RC28, a dual-target candidate drug for various eye diseases, which is the first of its kind to enter clinical trials globally[181]. - The company is actively promoting global multi-center clinical trials for its core products, aiming for early market approval and international expansion[182]. Corporate Governance and Compliance - The company received a standard unqualified audit report from Ernst & Young Hua Ming[4]. - The company has no violations of decision-making procedures for external guarantees[7]. - The company has established an international clinical and registration system to ensure global registration and commercialization of products[183]. - The board of directors consists of 9 members, including 3 independent directors, ensuring effective governance and decision-making[189]. - The company adheres to strict information disclosure management, ensuring timely and accurate communication with investors[190]. Risks and Challenges - The company faces potential short-term losses due to high expenses related to new drug applications and market promotion[3]. - The company emphasizes the risks associated with forward-looking statements regarding future plans and strategies[6]. - The company faces risks related to regulatory approvals and market competition, which could impact future revenue and profitability[123]. Human Resources and Management - The management team consists of experts with over 20 years of experience in the pharmaceutical industry, focusing on innovative drug development and commercialization strategies[119]. - The company has a total of 926 R&D personnel, accounting for 30.88% of the total workforce, down from 36.18% in the previous period[112]. - The average salary of R&D personnel is ¥48.52 thousand, an increase from ¥34.91 thousand in the previous period[112]. - The total pre-tax compensation for directors, supervisors, and senior management during the reporting period amounted to CNY 2,693.88 million[196].

荣昌生物（688331）3月24日主力资金净流入 1386.20万元 金融界消息 截至2025年3月24日收盘，荣昌生物（688331）报收于36.66元，上涨4.59%，换手率3.6%， 成交量5.82万手，成交金额2.11亿元。 资金流向方面，今日主力资金净流入1386.20万元，占比成交额6.57%。其中，超大单净流入390.13万 元、占成交额1.85%，大单净流入996.07万元、占成交额4.72%，中单净流出流入747.09万元、占成交额 3.54%，小单净流出2133.28万元、占成交额10.11%。 荣昌生物最新一期业绩显示，截至2024三季报，公司营业总收入12.09亿元、同比增长57.10%，归属净 利润107142.66万元，同比减少3.96%，扣非净利润109739.38万元，同比减少3.45%，流动比率1.356、速 动比率0.956、资产负债率58.54%。 天眼查商业履历信息显示，荣昌生物制药(烟台)股份有限公司，成立于2008年，位于烟台市，是一家以 从事医药制造业为主的企业。企业注册资本54433.2083万人民币，实缴资本40181.9202万人民币。公司 法定代表人为王威 ...

Financial Performance - The company achieved total operating revenue of 171,540.42 million yuan, a year-on-year increase of 58.40%[3] - The net profit attributable to the parent company was -146,786.25 million yuan, with a decrease in net profit excluding non-recurring gains and losses of -150,039.33 million yuan[5] - The basic earnings per share were -2.73 yuan, showing a slight improvement from -2.80 yuan in the previous year[3] - The weighted average return on net assets decreased to -54.06%, compared to -35.52% in the previous year[3] - The company expects a net loss for 2024, but with a trend towards reduced losses compared to the previous year[5] Assets and Equity - Total assets at the end of the reporting period were 549,914.78 million yuan, a decrease of 0.53% from the beginning of the period[4] - The equity attributable to the parent company decreased by 42.21% to 198,638.60 million yuan[4] Sales and Revenue Growth - The company reported a significant increase in sales revenue from innovative drugs, particularly from Tai Tasi Pi and Vidi Xi Tuo Monoclonal Antibody[7] - The gross profit margin of products continued to grow, while the sales expense ratio significantly decreased[5] Research and Development - The company is in the process of advancing multiple innovative drug candidates in critical trial phases, leading to increased R&D investment[5]

Revenue Projections - The company expects a revenue of approximately CNY 1,715 million for 2024, an increase of about CNY 632 million or 58% compared to the previous year[3]. - In 2023, the company reported a revenue of CNY 1,083 million and a total loss of CNY 1,511 million[6]. Net Loss Forecast - The projected net loss attributable to the parent company for 2024 is approximately CNY 1,470 million, a decrease of about CNY 41 million or 3% compared to the previous year[3]. - The expected net loss attributable to the parent company, excluding non-recurring gains and losses, is approximately CNY 1,498 million, a decrease of about CNY 45 million or 3% compared to the previous year[3]. Research and Development - The company is advancing its new drug research pipeline, with multiple innovative drugs in critical trial stages, leading to increased R&D investment[8]. Sales Performance - Sales revenue from Taitasip and Vidisitamab is growing rapidly, contributing to an increase in product gross margin[8]. - The sales expense ratio has significantly decreased, indicating improved operational efficiency[8]. Financial Reporting and Uncertainties - The total amount of non-recurring gains and losses for the year has not changed significantly[9]. - As of the announcement date, the company has not identified any major uncertainties affecting the accuracy of the performance forecast[10]. - The forecast data is preliminary and subject to change pending the audited financial report for 2024[11].

荣昌生物制药（烟台）股份有限公司监事会 2024 年 12 月 30 日 1 权益及 B 类权益对应归属期归属名单的核查意见 荣昌生物制药（烟台）股份有限公司（以下简称"公司"）监事会根据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以 下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理办法》"）、 《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）等相关法律、 法规及规范性文件和《荣昌生物制药（烟台）股份有限公司章程》（以下简称"《公 司章程》"）的有关规定，对公司 2022 年 A 股限制性股票激励计划（以下简称"本 激励计划"）之 A 类权益第二个归属期及 B 类权益首次授予第一个归属期符合归 属条件的激励对象名单进行审核，发表核查意见如下： 本次拟归属的激励对象符合《公司法》《证券法》等法律、法规和规范性文 件以及《公司章程》规定的任职资格，符合《管理办法》《上市规则》等法律、 法规和规范性文件规定的激励对象条件，符合本激励计划规定的激励对象范围， 其作为公司本激励计划激励对象的主体资格合法、有效，激励对象获授限制性股 票的归属条件已 ...

| 证券代码：688331 | 证券简称：荣昌生物 | 公告编号：2024-057 | | --- | --- | --- | | 港股代码：09995 | 港股简称：榮昌生物 | | 荣昌生物制药（烟台）股份有限公司 关于公司 2022 年 A 股限制性股票激励计划之 B 类权益首次 授予第一个归属期符合归属条件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本次股权激励计划批准及实施情况 （一）本次股权激励计划主要内容 1、股权激励方式：第二类限制性股票。 2、授予数量：本激励计划向激励对象授予的限制性股票数量为 358.000 万 股，约占本激励计划草案公告时公司股本总额 54,426.30 万股的 0.6578%。其中， 首次授予 A 类权益 87.305 万股，B 类权益 199.64 万股，合计 286.945 万股，约 占本激励计划草案公告时公司股本总额 54,426.30 万股的 0.5272%，首次授予部 分占本次授予权益总额的 80.15%；预留 71.055 万股，约占本激 ...

| 证券代码：688331 | 证券简称：荣昌生物 | 公告编号：2024-051 | | --- | --- | --- | | 港股代码：09995 | 港股简称：榮昌生物 | | 荣昌生物制药（烟台）股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 12 月 10 日(星期二) 上午 10:00-11:00 会议召开地点： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 12 月 03 日(星期二) 至 12 月 09 日(星期一)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@remegen.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 三、 参加人员 董事长：王威东先生 总经理：房健民先生 董事会秘书：温庆凯先生 荣昌生 ...

Revenue and Profitability - Revenue for Q3 2024 reached ¥467,117,500.34, representing a year-on-year increase of 34.60%[3] - Net profit attributable to shareholders was -¥290,966,871.21, with a cumulative net profit of -¥1,071,426,638.90 year-to-date[3] - Total operating revenue for the first three quarters of 2024 reached ¥1,208,874,280.23, a significant increase from ¥769,470,314.65 in the same period of 2023, representing a growth of approximately 56.9%[16] - Net profit for the third quarter of 2024 was a loss of ¥1,071,426,638.90, slightly worse than the loss of ¥1,030,585,859.60 in the same quarter of 2023[19] - The company reported a basic and diluted earnings per share of ¥-1.99 for the third quarter of 2024, compared to ¥-1.91 in the same quarter of 2023[19] Research and Development - Research and development expenses totaled ¥347,174,784.03, accounting for 74.32% of revenue, a decrease of 17.17 percentage points compared to the previous year[4] - Research and development expenses for the first three quarters of 2024 amounted to ¥1,153,407,440.34, up from ¥857,977,852.40 in 2023, reflecting a growth of approximately 34.4%[18] - The company experienced a decline in equity attributable to shareholders, down 31.09% due to increased losses from R&D investments[7] - Future outlook includes continued focus on research and development of new products and technologies to drive growth[12] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,712,713,413.00, an increase of 3.34% from the previous year[4] - The company's current assets totaled RMB 2,524,007,322.36, up from RMB 2,228,931,955.16 at the end of 2023, indicating a growth of approximately 13.2%[13] - Total liabilities as of the end of the third quarter of 2024 were ¥3,344,032,874.19, compared to ¥2,090,972,550.70 in 2023, showing an increase of about 60.0%[18] - The total equity attributable to shareholders of the parent company was ¥2,368,680,538.81, down from ¥3,437,268,153.89 in the previous year, indicating a decrease of approximately 30.9%[18] Cash Flow - Cash flow from operating activities was not applicable for the current period, with a cumulative negative cash flow of -¥835,103,066.88 year-to-date[3] - Cash inflow from operating activities totaled ¥1,222,172,614.37 for the first three quarters of 2024, compared to ¥718,145,797.69 in 2023, marking an increase of about 70.0%[20] - Cash flow from operating activities for the first three quarters of 2024 was negative at ¥-835,103,066.88, an improvement compared to ¥-1,114,762,180.68 in the same period of 2023[20] - Net cash flow from investment activities was -¥425.81 million, an improvement from -¥920.37 million year-over-year[21] - Total cash inflow from financing activities reached ¥1,316.63 million, up from ¥659.28 million, representing a 99.5% increase[21] - Net cash flow from financing activities was ¥1,202.06 million, compared to ¥511.63 million in the previous period, showing a significant increase of 134%[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,618[8] - The company reported a total of 7,594 A-share common stockholders and 24 H-share common stockholders as of the report date[11] - The top 10 shareholders held a total of 189,566,728 shares, representing 34.83% of the total shares outstanding[9] Market Position and Strategy - The company reported a significant increase in sales of injectable drugs, specifically TaiTasi and VidiXimab, contributing to revenue growth[7] - The company has engaged in strategic partnerships and investments to enhance its market position and expand its product offerings[12] Government Support - Government subsidies recognized in the current period amounted to ¥17,816,478.70, impacting the overall financial performance positively[5]

Financial Performance - The company's operating revenue for Q3 2024 was ¥467,117,500.34, representing a year-on-year increase of 34.60%[2] - The net profit attributable to shareholders was -¥290,966,871.21, with a year-to-date net profit of -¥1,071,426,638.90[2] - Total operating revenue for the first three quarters of 2024 reached ¥1,208,874,280.23, a significant increase from ¥769,470,314.65 in the same period of 2023, representing a growth of approximately 56.9%[14] - The net loss for the first three quarters of 2024 was ¥1,071,426,638.90, compared to a net loss of ¥1,030,585,859.60 in the same period of 2023, showing a slight increase in losses[16] - The basic and diluted earnings per share were both -¥0.54 for Q3 2024, with a year-to-date figure of -¥1.99[3] - The basic and diluted earnings per share for the first three quarters of 2024 were both -¥1.99, compared to -¥1.91 in 2023, indicating a slight deterioration in per-share performance[17] Research and Development - Research and development expenses totaled ¥347,174,784.03 in Q3 2024, accounting for 74.32% of operating revenue, a decrease of 17.17 percentage points compared to the same period last year[3] - Research and development expenses surged to ¥1,153,407,440.34 in the first three quarters of 2024, compared to ¥857,977,852.40 in 2023, reflecting a rise of approximately 34.4%[14] - The total equity attributable to shareholders decreased by 31.09% year-on-year, primarily due to increased losses from higher R&D expenditures[6] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,712,713,413.00, an increase of 3.34% from the end of the previous year[3] - The total liabilities increased to ¥3,344,032,874.19 in 2024 from ¥2,090,972,550.70 in 2023, marking an increase of approximately 60.0%[13] - The total equity attributable to shareholders decreased to ¥2,368,680,538.81 in 2024 from ¥3,437,268,153.89 in 2023, a decline of about 30.9%[13] Cash Flow - The cash flow from operating activities was not applicable for the current period, with a year-to-date net cash flow of -¥835,103,066.88[2] - In the first three quarters of 2024, the company generated cash inflows from operating activities totaling approximately ¥1.22 billion, compared to ¥718.15 million in the same period of 2023, representing a year-over-year increase of 70%[18] - The net cash flow from operating activities for the first three quarters of 2024 was approximately -¥835.10 million, an improvement from -¥1.11 billion in the same period of 2023[18] - The total cash outflow from operating activities was approximately ¥2.06 billion in 2024, compared to ¥1.83 billion in 2023, indicating an increase of about 12%[18] Shareholder Information - The company reported a total of 7,618 shareholders, with 7,594 being A-share holders and 24 being H-share holders[9] - The top 10 shareholders include HKSCC NOMINEES LIMITED holding 189,566,728 shares, representing 34.83% of total shares[9] Government Support - The company received government subsidies amounting to ¥17,816,478.70 during the reporting period, contributing to its other income[4] Interest and Other Income - The company reported a significant increase in interest expenses, which rose to ¥55,598,761.08 in 2024 from ¥13,656,827.51 in 2023[16] - Other comprehensive income after tax for the first three quarters of 2024 was negative at -¥42,366,321.69, compared to -¥7,908,770.97 in 2023, indicating a worsening position[17] Product Development - The company reported a significant increase in sales revenue due to higher sales volumes of its injectable products, specifically TaiTasi and VidiXimab[6] - The company is actively involved in the development of new products and technologies, focusing on market expansion strategies[10]